Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305016 · ClinicalTrials.gov registry record · Phase 3
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
A Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 146
- Enrollment target
NCT03305016: Completed Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
NCT03305016 is a Phase 3 study that has completed, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 146 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305016, a Phase 3 study, has completed, sponsored by Ascendis Pharma Endocrinology Division A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 146 participants
- Enrollment target
Study Summary
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
Primary Outcome
Safety and tolerability of weekly lonapegsomatropin (TransCon hGH) treatment
Interventions
- DRUG TransCon hGH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 3 |
What the finished NCT03305016 record still lists
NCT03305016 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which TransCon hGH is the first listed.
NCT03305016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03305016 about?
NCT03305016 is a clinical study titled "A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency". A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, b...
What is the current status of trial NCT03305016?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 146 participants. The study started on 2017-11-13. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03305016?
The interventions under investigation include: TransCon hGH (DRUG).
Who is sponsoring clinical trial NCT03305016?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03305016's enrollment target sits among peer trials
146 1551st of 2000 higher than 446 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI